The understanding of cancer's genetic basis has revolutionized oncology, paving the way for personalized medicine.  Advances in next-generation sequencing (NGS) technologies have enabled comprehensive genomic profiling of tumors, revealing the complex interplay of somatic mutations, copy number variations, and epigenetic alterations driving tumorigenesis. This wealth of data allows for the identification of specific driver mutations, informing targeted therapies tailored to individual patient profiles.  Recent developments include the application of liquid biopsies, which utilize circulating tumor DNA (ctDNA) to non-invasively monitor disease progression and response to treatment, thereby facilitating earlier detection and adaptive therapy strategies. Furthermore, advancements in CRISPR-Cas9 gene editing technology hold immense promise for correcting deleterious mutations or enhancing immune responses against cancer cells.  While challenges remain in translating these genomic insights into effective clinical practice, including the identification of actionable mutations and the management of treatment resistance, the ongoing integration of genomics, immunology, and bioinformatics promises increasingly precise and effective personalized cancer therapies. This progress signifies a shift from generalized approaches towards truly individualized treatment strategies, maximizing efficacy and minimizing adverse effects.